RxDoctor Payments Data

Kenneth Levin, MD

Neurology · Ridgewood, NJNPI 1679534515

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $72,068 of the $76,653 with a category attached, or 94.0%. Every reported general payment came from a single manufacturer, AbbVie. Reporting peaked in 2022 at $18,047 and has fallen 98.8% since, to $211 in 2025. Among neurology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$76,653in general payments, 2019–2025

Across 204 payments — averaging $375.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$77K

What the payments were for

  • Speaking & faculty fees$72,06894%
  • Travel & lodging$1,5542%
  • Food & beverage$3,0324%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)204$76,653

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,653 in reported general payments places this provider in the 90th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$967,451
Medicare patients
320
Services billed
128,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina16$30,502
UbrelvyUbrogepant21$22,354
DilantinPhenytoin Sodium Extended16$5,737
OxycontinOxycodone Hcl11$4,691
Sumatriptan Succinate27$3,250
Gabapentin54$1,030
Galantamine ErGalantamine Hbr11$751
Clonazepam47$628
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine22$460
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$454
Donepezil Hcl18$425
Escitalopram Oxalate12$214
Quetiapine Fumarate11$155
Diazepam22$132
Oxycodone Hcl11$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy$76,653$52,85537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 521 neurology providers in New Jersey.

Other neurology in Ridgewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →